Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385003 | 0.89 | MEN1 (0.48) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL31390483 | 0.84 | NPC1 (0.43) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL5228223 | 0.83 | MDM4 (0.62) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL5225778 | 0.82 | MEN1 (0.47) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL1435144 | 0.82 | HDAC1 (0.54) | HDAC1MEN1KMT2ANAMPTF10 | |
| SCHEMBL31390513 | 0.81 | NPC1 (0.44) | HDAC1AHR | |
| SCHEMBL27617174 | 0.81 | P4HTM (0.49) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL3219129 | 0.81 | HDAC1 (0.45) | HDAC1MEN1AHRKMT2AP4HTM | |
| SCHEMBL22874499 | 0.81 | P4HTM (0.65) | MEN1AHRKMT2AP4HTM | |
| SCHEMBL3219143 | 0.81 | HDAC1 (0.46) | HDAC1MEN1AHRKMT2AP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | MKI67, API5, ACIN1 | HDAC1 757/4885MEN1 3616/4885AHR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.